Cargando…

Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials

Cushing's disease (CD) is a serious endocrine disorder characterized by chronic hypercortisolism, or Cushing's syndrome (CS), caused by a corticotroph pituitary tumor, which induces an excessive adrenocorticotropic hormone (ACTH) and consequently cortisol secretion. CD presents a severe cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pivonello, Rosario, Ferrigno, Rosario, De Martino, Maria Cristina, Simeoli, Chiara, Di Paola, Nicola, Pivonello, Claudia, Barba, Livia, Negri, Mariarosaria, De Angelis, Cristina, Colao, Annamaria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753248/ https://www.ncbi.nlm.nih.gov/pubmed/33363514 http://dx.doi.org/10.3389/fendo.2020.00648

Ejemplares similares

Neuropsychiatric disorders in Cushing's syndrome
por: Pivonello, Rosario, et al.
Publicado: (2015)

Cushing’s disease: adrenal steroidogenesis inhibitors
por: Pivonello, Rosario, et al.
Publicado: (2022)

Influence of Bisphenol A on Type 2 Diabetes Mellitus
por: Provvisiero, Donatella Paola, et al.
Publicado: (2016)

SUN-358 Dual Release Hydrocortisone as a New Treatment for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
por: Simeoli, Chiara, et al.
Publicado: (2019)

Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit
por: Provvisiero, Donatella Paola, et al.
Publicado: (2019)

The dopaminergic control of Cushing’s syndrome
por: Pivonello, R., et al.
Publicado: (2022)

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
por: Pivonello, Claudia, et al.
Publicado: (2022)

Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment
por: Pirchio, Rosa, et al.
Publicado: (2021)

The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma
por: Pivonello, Claudia, et al.
Publicado: (2016)

Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma
por: Negri, Mariarosaria, et al.
Publicado: (2022)

Vitamin D-Induced Molecular Mechanisms to Potentiate Cancer Therapy and to Reverse Drug-Resistance in Cancer Cells
por: Negri, Mariarosaria, et al.
Publicado: (2020)

The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center
por: Simeoli, C., et al.
Publicado: (2019)

Metabolic Disorders and Male Hypogonadotropic Hypogonadism
por: Pivonello, Rosario, et al.
Publicado: (2019)

The role of mTOR pathway as target for treatment in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess
por: Pivonello, Rosario, et al.
Publicado: (2020)

The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets
por: Pivonello, Claudia, et al.
Publicado: (2014)

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant
por: Pivonello, Rosario, et al.
Publicado: (2022)

Metabolic effects of prolactin
por: Pirchio, Rosa, et al.
Publicado: (2022)

Glucose Abnormalities Associated to Prolactin Secreting Pituitary Adenomas
por: Auriemma, Renata S., et al.
Publicado: (2019)

Testis-Specific Genes Deregulation in the Testis of COVID-19 Patients: A Potential Driver of Spermatogenesis Disruption?
por: Pivonello, Rosario, et al.
Publicado: (2022)

Severe impact of late diagnosis of congenital adrenal hyperplasia on gender identity, sexual orientation and function: case report and review of the literature
por: Simeoli, Chiara, et al.
Publicado: (2022)

The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology
por: Auriemma, Renata S., et al.
Publicado: (2020)

A New Clinical Model to Estimate the Pre-Test Probability of Cushing’s Syndrome: The Cushing Score
por: Parasiliti-Caprino, Mirko, et al.
Publicado: (2021)

Imbalanced cortisol concentrations in glycogen storage disease type I: evidence for a possible link between endocrine regulation and metabolic derangement
por: Rossi, Alessandro, et al.
Publicado: (2020)

Approach to patients with pseudo-Cushing’s states
por: Scaroni, Carla, et al.
Publicado: (2019)

The role of melatonin in the molecular mechanisms underlying metaflammation and infections in obesity: A narrative review
por: Pivonello, Claudia, et al.
Publicado: (2021)

The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications
por: Isidori, Andrea M., et al.
Publicado: (2015)

The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

Levoketoconazole in the Treatment of Patients With Cushing’s Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study
por: Pivonello, Rosario, et al.
Publicado: (2021)

Approach to the Patient With Prolactinoma
por: Auriemma, Renata S, et al.
Publicado: (2023)

MicroRNAs and Long Non-Coding RNAs in Adrenocortical Carcinoma
por: Detomas, Mario, et al.
Publicado: (2022)

Bisphenol A: an emerging threat to female fertility
por: Pivonello, Claudia, et al.
Publicado: (2020)

Smoke, alcohol and drug addiction and female fertility
por: de Angelis, Cristina, et al.
Publicado: (2020)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023)

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
por: Pivonello, Rosario, et al.
Publicado: (2021)

Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
por: Pivonello, Rosario, et al.
Publicado: (2022)

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

THU035 Impact Of Surgery Or Medical Treatment With The Selective Glucocorticoid Receptor Modulator Relacorilant On Hypercoagulopathy In Patients With Cushing Syndrome
por: Simeoli, Chiara, et al.
Publicado: (2023)

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”
por: Pivonello, Rosario, et al.
Publicado: (2019)

Long-term high-dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial
por: Menafra, D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6oglmrkd30oghh9fdcjl92d9hn